Advanced Machine Intelligence (AMI Labs), a startup co-founded by Turing Award laureate Yann LeCun and Nabla founder Alex LeBrun, has successfully completed a notable $1.03 billion seed funding round, valuing the company at $3.5 billion pre-money. The considerable investment emphasizes the growing interest in innovative artificial intelligence applications within the healthcare sector, particularly as AMI seeks to redefine clinical decision-making through new technological models.
Nabla, a clinical AI company, has established an exclusive strategic partnership with AMI Labs, granting it first access to the startup’s emerging AI models. In a significant leadership transition, Alex LeBrun will step into the role of CEO at AMI Labs while continuing his responsibilities as Chairman and Chief AI Scientist at Nabla. This connection aims to leverage AMI’s advancements to enhance Nabla’s operational capabilities within the healthcare ecosystem.
The current landscape of large language models (LLMs) highlights notable limitations in their application for clinical settings. While these models excel in tasks such as clinical documentation and knowledge retrieval, they fundamentally operate as probabilistic text generators. This characteristic poses challenges for autonomous clinical decision-making, where deterministic reasoning is essential. For instance, an LLM cannot accurately assess the implications of prescribing a specific medication to a patient with unique comorbidities, nor can it manage the complex, multimodal data typically encountered in intensive care environments.
AMI Labs is shifting from the conventional LLM framework to develop what it terms “world models.” These systems aim to construct abstract representations of real-world scenarios, allowing for simulations that predict how situations evolve and how actions yield specific consequences. AMI’s technology facilitates a form of reasoning that can anticipate outcomes before an intervention is executed—an essential capability for meeting regulatory standards from bodies like the FDA. This transition underscores the demand for AI systems that can operate autonomously while ensuring safe, auditable decision-making processes.
Nabla’s ambition to employ AMI’s world models aligns with its existing integration into clinical workflows. The company has already deployed its ambient AI assistant across hundreds of health systems, focusing initially on documentation tasks. However, the broader vision encompasses the development of Agentic AI systems capable of performing various clinical actions. Such systems could streamline processes by not only drafting referral notes but also navigating scheduling systems, assessing insurance limitations, booking specialists, and preparing necessary lab orders—all within a framework of persistent memory and safety protocols.
The implications of this technological evolution are significant. As healthcare systems increasingly rely on AI to enhance operational efficiency and improve patient outcomes, the shift from LLMs to more sophisticated world models represents a critical advancement. By enabling more robust and context-aware decision-making capabilities, AMI Labs and Nabla aim to pioneer a new frontier in healthcare technology that not only meets clinical needs but also adheres to strict regulatory standards. This development could redefine how healthcare professionals interact with AI, potentially leading to more integrated and effective patient care strategies in the future.
See also
Meta’s Oversight Board Urges Overhaul of AI Deepfake Detection Amid Rising Misinformation
NVIDIA Jetson Launches AI Edge Solutions with Open Models for Real-Time Industrial Applications
European Parliament Adopts Copyright Report on Generative AI with 460 Votes for Fairness
Google Reveals 10 Must-Try AI Tools, Transforming Workflows for 2026 Professionals
EU Proposes AI Image Generation Safeguards to Prevent Exploitation of Minors
